

Inflammation: Chronic

REFERENCES

- Boldt J, Brosch C, Piper SN, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. *Crit Care Med*. 2001 May;29(5):952-8.
- Brock TG, McNish RW, Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. *J Biol Chem*. 1999 Apr 23;274(17):11660-6.
- Brod SA. Unregulated inflammation shortens human functional longevity. *Inflamm Res*. 2000 Nov;49(11):561-70.
- Brouqui P, Dumler JS, Raoult D. Immunohistologic demonstration of *Coxiella burnetii* in the valves of patients with Q fever endocarditis. *Am J Med*. 1994 Nov;97(5):451-8.
- Casson PR, Andersen RN, Herrod HG, et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. *Am J Obstet Gynecol*. 1993 Dec;169(6):1536-9.
- Das UN, Ramadevi G, Rao KP, et al. Prostaglandins can modify gamma-radiation and chemical induced cytotoxicity and genetic damage in vitro and in vivo. *Prostaglandins*. 1989 Dec;38(6):689-716.
- Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? *Prostaglandins Leukot Essent Fatty Acids*. 2000 Dec;63(6):351-62.
- De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. *Rheum Dis Clin North Am*. 1998 Nov;24(4):785-x.
- de la Cruz JP, Romero MM, Sanchez P, et al. Antiplatelet effect of pentoxifylline in human whole blood. *Gen Pharmacol*. 1993 May;24(3):605-9.
- Deon D, Ahmed S, Tai K, et al. Cross-talk between IL-1 and IL-6 signaling pathways in rheumatoid arthritis synovial fibroblasts. *J Immunol*. 2001 Nov 1;167(9):5395-403.
- Devaraj S, Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. *Free Radic Biol Med*. 2000 Oct 15;29(8):790-2.
- Devaux B, Scholz D, Hirche A, et al. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. *Eur Heart J*. 1997 Mar;18(3):470-9.
- Entzian P, Bitter-Suermann S, Burdon D, et al. Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? *Allergy*. 1998 Aug;53(8):749-54.
- Fan YY, Ramos KS, Chapkin RS. Dietary gamma-linolenic acid enhances mouse macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell proliferation. *J Nutr*. 1997 Sep;127(9):1765-71.
- Fischer M, Wohlrab J, Marsch W. Crux medicorum ulcerated radiation-induced fibrosis - successful therapy with pentoxifylline and vitamin E. *Eur J Dermatol*. 2001 Jan;11(1):38-40.
- Flint H, Cotter MA, Cameron NE. Pentoxifylline effects on nerve conduction velocity and blood flow in diabetic rats. *Int J Exp Diabetes Res*. 2000;1(1):49-58.
- Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci*. 2001 Mar;56(3):M146-M156.
- Gara II. [The effect of pentoxifylline and nicergoline on the systemic and cerebral hemodynamics and on the blood rheological

properties in patients with an ischemic stroke and atherosclerotic lesions of the major cerebral arteries]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1993;93(3):28-32.

Gaur SP, Garg RK, Kar AM, et al. Effect of anti-platelet therapy (aspirin + pentoxifylline) on plasma lipids in patients of ischaemic stroke. Indian J Physiol Pharmacol. 1993 Apr;37(2):158-60.

Gilhar A, Grossman N, Kahanovicz S, et al. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. In vitro and in vivo studies. Acta Derm Venereol. 1996 Nov;76(6):437-41.

Godwin-Austen RB, Twomey JA, Hanks G, et al. Oxpentifylline in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1980 Apr;43(4):360-4.

Gomez-Cambronero L, Camps B, de La Asuncion JG, et al. Pentoxifylline ameliorates cerulein-induced pancreatitis in rats: role of glutathione and nitric oxide. J Pharmacol Exp Ther. 2000 May;293(2):670-6.

Gosset P, Wallaert B, Tonnel AB, et al. Thiol regulation of the production of TNF-alpha, IL-6 and IL-8 by human alveolar macrophages. Eur Respir J. 1999 Jul;14(1):98-105.

Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999 May;106(5):506-12.

Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol. 2001 Apr;2(4):353-60.

Invitti C. [Obesity and low-grade systemic inflammation]. Minerva Endocrinol. 2002 Sep;27(3):209-14.

James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S.

Jeyarajah DR, Kielar M, Penfield J, et al. Docosahexaenoic acid, a component of fish oil, inhibits nitric oxide production in vitro. J Surg Res. 1999 May 15;83(2):147-50.

Kelley VE, Ferretti A, Izui S, et al. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol. 1985 Mar;134(3):1914-9.

Kreisberg JI, Patel PY. The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells. Prostaglandins Leukot Med. 1983 Aug;11(4):431-42.

Kremer JM. n-3 fatty acid supplements in rheumatoid arthritis. Am J Clin Nutr. 2000 Jan;71(1 Suppl):349S-51S.

Lee H, Liao JJ, Graeler M, et al. Lysophospholipid regulation of mononuclear phagocytes. Biochim Biophys Acta. 2002 May 23;1582(1-3):175-7.

Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999 Jul;4(4):317-27.

Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000 Oct 19;343(16):1139-47.

Marsella R, Olivry T. The ACVD task force on canine atopic dermatitis (XXII): nonsteroidal anti-inflammatory pharmacotherapy. Vet Immunol Immunopathol. 2001 Sep 20;81(3-4):331-45.

McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1999 May;52(5):465-77.

Moser M, Zhang M, Gong Y, et al. Effect of preoperative interventions on outcome following liver resection in a rat model of cirrhosis. J Hepatol. 2000 Feb;32(2):287-92.

Navarro JF, Mora C, Rivero A, et al. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. *Am J Kidney Dis.* 1999 Mar;33(3):458-63.

Navarro JF, Mora C, Garcia J, et al. Effects of pentoxifylline on the haematologic status in anaemic patients with advanced renal failure. *Scand J Urol Nephrol.* 1999 Apr;33(2):121-5.

Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. *Immunology.* 1994 Oct;83(2):262-7.

Noel C, Copin MC, Hazzan M, et al. Immunomodulatory effect of pentoxifylline during human allograft rejection: involvement of tumor necrosis factor-alpha and adhesion molecules. *Transplantation.* 2000 Mar 27;69(6):1102-7.

Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med.* 2000 Oct 19;343(16):1148-55.

PDR. Pentoxifylline (Trental).2004:1286.

Pollice PF, Rosier RN, Looney RJ, et al. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loosening of total joint components. *J Bone Joint Surg Am.* 2001 Jul;83-A(7):1057-61.

Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. *JAMA.* 2001 Jul 18;286(3):327-34.

Purasiri P, Murray A, Richardson S, et al. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. *Clin Sci (Lond).* 1994 Dec;87(6):711-7.

Rader DJ. Inflammatory markers of coronary risk. *N Engl J Med.* 2000 Oct 19;343(16):1179-82.

Reddi K, Henderson B, Meghji S, et al. Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (vitamin K) compounds. *Cytokine.* 1995 Apr;7(3):287-90.

Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med.* 1997 Apr 3;336(14):973-9.

Sampaio EP, Moraes MO, Nery JA, et al. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). *Clin Exp Immunol.* 1998 Feb;111(2):300-8.

Santoro A, Mancini E. Cardiac effects of chronic inflammation in dialysis patients. *Nephrol Dial Transplant.* 2002;17 Suppl 8:10-5.

Schwarz A, Krone C, Trautinger F, et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. *J Invest Dermatol.* 1993 Oct;101(4):549-52.

Segal R, Dayan M, Zinger H, et al. Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline. *Lupus.* 2001;10(1):23-31.

Serrano-Duenas M. [Parkinsonism or Parkinson's disease unmasked by pentoxifylline?]. *Neurologia.* 2001 Jan;16(1):39-42.

Sitzer M, Markus HS, Mendall MA, et al. C-reactive protein and carotid intimal medial thickness in a community population. *J Cardiovasc Risk.* 2002 Apr;9(2):97-103.

Stigendal L, Andre U, Christenson B. [Better AVK treatment with self monitoring. Dosage can be regulated in time]. *Lakartidningen.* 1999 May 19;96(20):2482, 2485-2, 2487.

Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. *Lancet.* 2001 Sep 1;358(9283):696-701.

Teucher T, Obertreis B, Ruttkowski T, et al. [Cytokine secretion in whole blood of healthy subjects following oral administration of *Urtica dioica* L. plant extract]. *Arzneimittelforschung.* 1996 Sep;46(9):906-10.

van der Meide PH, Schellekens H. Cytokines and the immune response. *Biotherapy*. 1996;8(3-4):243-9.

Vazquez Garcia MJ, Vargas Camano ME, Olalde CR. [Use of pentoxifylline in pediatric patients with grade IV (OMS) lupus nephropathy who have received multiple treatments]. *Rev Alerg Mex*. 2000 May;47(3):109-14.

Ventura AC, Bohnke M. Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival. *Br J Ophthalmol*. 2001 Sep;85(9):1110-4.

Verdecchia P, Reboldi G, Porcellati C, et al. Risk of cardiovascular disease in relation to achieved office and ambulatory blood pressure control in treated hypertensive subjects. *J Am Coll Cardiol*. 2002 Mar 6;39(5):878-85.

Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Circadian interleukin-6 secretion and quantity and depth of sleep. *J Clin Endocrinol Metab*. 1999 Aug;84(8):2603-7.

Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. *J Clin Endocrinol Metab*. 2001 Aug;86(8):3787-94.

Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. *Proc Natl Acad Sci U S A*. 2002 Nov 26;99(24):15596-601.

Ward PA. Cytokines, inflammation, and autoimmune diseases. *Hosp Pract (Off Ed)*. 1995 May 15;30(5):35-41.

Watanabe S, Katagiri K, Onozaki K, et al. Dietary docosahexaenoic acid but not eicosapentaenoic acid suppresses lipopolysaccharide-induced interleukin-1 beta mRNA induction in mouse spleen leukocytes. *Prostaglandins Leukot Essent Fatty Acids*. 2000 Mar;62(3):147-52.

Weber P. Management of osteoporosis: is there a role for vitamin K? *Int J Vitam Nutr Res*. 1997;67(5):350-6.

Welsh O, Gomez M, Mancias C, et al. A new therapeutic approach to type II leprosy reaction. *Int J Dermatol*. 1999 Dec;38(12):931-3.

White RH, McCurdy SA, von Marenzendorff H, et al. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. *Ann Intern Med*. 1989 Nov 1;111(9):730-7.

Willard LB, Hauss-Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. *Neuroscience*. 1999 Jan;88(1):193-200.

Yano M, Kishida E, Iwasaki M, et al. Docosahexaenoic acid and vitamin E can reduce human monocytic U937 cell apoptosis induced by tumor necrosis factor. *J Nutr*. 2000 May;130(5):1095-101.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

LifeExtension[®]

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.